54 results
424B5
LRMR
Larimar Therapeutics Inc
14 Feb 24
Prospectus supplement for primary offering
5:08pm
, unforeseen emergencies and other outbreaks of communicable diseases, including the ongoing COVID-19 pandemic and the efforts to mitigate
424B5
LRMR
Larimar Therapeutics Inc
13 Feb 24
Prospectus supplement for primary offering
4:46pm
health epidemics, unforeseen emergencies and other outbreaks of communicable diseases, including the ongoing COVID-19 pandemic and the efforts to mitigate
8-K
EX-99.1
jm9ggv
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.2
obcso0g 03bv9abogd
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
3x3i g3kep0dirq
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
424B5
76j27 gpeykaan3z2
14 Sep 22
Prospectus supplement for primary offering
7:28am
8-K
EX-99.2
vlx0 yrpj4k
14 Sep 22
Other Events
7:05am
8-K
EX-99.1
y3q4mrabzh2 dw8kf
14 Sep 22
Other Events
7:05am
8-K
EX-99.1
y93fdn3me
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.2
5zab466piyegtjbdx
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.2
9ey2ussrtxn9
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.1
rs6jl6ra
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.1
g6l9k9ls4313
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am